As of close of business last night, AbbVie Inc.’s stock clocked out at $138.62, down -1.79% from its previous closing price of $141.15. In other words, the price has decreased by -$2.53 from its previous closing price. On the day, 6707009 shares were traded. ABBV stock price reached its highest trading level at $140.20 during the session, while it also had its lowest trading level at $138.26.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
To gain a deeper understanding of ABBV’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 35.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.12. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 1.00. In the meantime, Its Debt-to-Equity ratio is 4.68 whereas as Long-Term Debt/Eq ratio is at 4.47.
Upgrades & Downgrades
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 25 when Sorg Elaine K. sold 6,130 shares for $165.00 per share. The transaction valued at 1,011,450 led to the insider holds 35,330 shares of the business.
Sorg Elaine K. sold 7,499 shares of ABBV for $1,212,338 on Apr 17. The SVP, US COMMERCIAL OPERATIONS now owns 35,330 shares after completing the transaction at $161.67 per share. On Apr 03, another insider, Sorg Elaine K., who serves as the SVP, US COMMERCIAL OPERATIONS of the company, sold 15,002 shares for $160.03 each. As a result, the insider received 2,400,770 and left with 42,829 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 267.48B and an Enterprise Value of 321.52B. As of this moment, AbbVie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 32.71, and their Forward P/E ratio for the next fiscal year is 12.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.26 while its Price-to-Book (P/B) ratio in mrq is 18.48. Its current Enterprise Value per Revenue stands at 5.67 whereas that against EBITDA is 24.45.
Stock Price History:
Over the past 52 weeks, ABBV has reached a high of $168.11, while it has fallen to a 52-week low of $134.09. The 50-Day Moving Average of the stock is 154.05, while the 200-Day Moving Average is calculated to be 150.75.
It appears that ABBV traded 5.71M shares on average per day over the past three months and 4.86M shares per day over the past ten days. A total of 1.77B shares are outstanding, with a floating share count of 1.76B. Insiders hold about 0.13% of the company’s shares, while institutions hold 70.90% stake in the company. Shares short for ABBV as of May 14, 2023 were 11.97M with a Short Ratio of 11.97M, compared to 15.14M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 0.68% and a Short% of Float of 0.68%.
Dividends & Splits
With its trailing 12-month dividend rate of 5.78, ABBV has a forward annual dividend rate of 5.92. Against a Trailing Annual Dividend Yield of 4.09%, it implies a Forward Annual Dividend Yield of 4.19%. The stock’s 5-year Average Dividend Yield is 4.44.
As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $2.93 for the current quarter, with a high estimate of $2.99 and a low estimate of $2.86, while EPS last year was $3.37. The consensus estimate for the next quarter is $2.83, with high estimates of $3.1 and low estimates of $2.55.
Analysts are recommending an EPS of between $11.14 and $10.63 for the fiscal current year, implying an average EPS of $10.96. EPS for the following year is $11.08, with 22 analysts recommending between $12.35 and $9.58.
In the current quarter, 12 analysts expect revenue to total $13.53B. It ranges from a high estimate of $13.67B to a low estimate of $13.39B. As of the current estimate, AbbVie Inc.’s year-ago sales were $14.58B, an estimated decrease of -7.30% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $13.38B, a decrease of -10.20% less than the figure of -$7.30% in the same quarter last year. There is a high estimate of $13.65B for the next quarter, whereas the lowest estimate is $13.08B.
A total of 20 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $54.19B, while the lowest revenue estimate was $52.21B, resulting in an average revenue estimate of $52.68B. In the same quarter a year ago, actual revenue was $58.05B, down -9.30% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $52.32B in the next fiscal year. The high estimate is $55.16B and the low estimate is $49.42B. The average revenue growth estimate for next year is down -0.70% from the average revenue estimate for this year.